SCHEMBL2645663

SCHEMBL2645663

CON(C)C(=O)[C@H]1C[C@@H](O)CN1C(=O)O

nearest known ligand 0.45

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.45
ALDH1A1 P00352 1/20 0.38
MMP2 P08253 2/20 0.33
ANPEP P15144 2/20 0.33
PIK3CD O00329 2/20 0.33
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3891979 1.00 ATM (0.45) ATMALDH1A1MMP2ANPEPPIK3CD
SCHEMBL20973270 0.83 ATM (0.50) ATMALDH1A1PIK3CD
SCHEMBL6002159 0.83 ATM (0.50) ATMALDH1A1PIK3CD
SCHEMBL5065994 0.83 ATM (0.50) ATMALDH1A1PIK3CD
SCHEMBL2498387 0.83 ATM (0.50) ATMALDH1A1PIK3CD
SCHEMBL5068787 0.83 ATM (0.50) ATMALDH1A1PIK3CD
SCHEMBL25258303 0.83 PEPD (0.35)
SCHEMBL25259533 0.83 UCHL1 (0.38)
SCHEMBL25261946 0.83 PEPD (0.35)
SCHEMBL25259584 0.83 UCHL1 (0.38)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1702919-B1 NOVEL 2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE MSD KK (JP) 2012-05-30 EP disclosed
US-7728025-B2 2-heteroaryl-substituted benzimidazole derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-06-01 US disclosed
US-20080070928-A1 Novel 2-Heteroaryl-Substituted Benzimidazole Derivative MSD K.K. (JP) 2008-03-20 US disclosed
EP-1702919-A1 NOVEL 2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-09-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080070928-A1 Novel 2-Heteroaryl-Substituted Benzimidazole Derivative GCK, GCKR, HK1 ATM 896/4885ALDH1A1 1188/4885MMP2 265/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.